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CPPs are short peptides [1]. Most of them are positively charged,
and despite their polarity, either alone or with a cargo, they traversecell membranes. The capacity to drag a partner into cell is used to
target drugs in cells. Design of CPP is an active scientiﬁc ﬁeld stim-
ulated by potential therapeutic applications. It is based on compre-
hensive analyses of structural and functional data.
Experimentally, the approach of peptide structure is uneasy. CD,
FTIR, X-ray, and NMR have been and are largely used and often give
differentmodels for the same peptide. In silico calculations of 3Dmodels
of peptides were also developed, and as previously reviewed, available
algorithms could give different structures [2]. It is clear now that both
2218 A. Thomas et al. / Biochimica et Biophysica Acta 1798 (2010) 2217–2222experimental and modeling approaches of peptide structures were
misled by the assumption that a peptide had to have a single (at most a
few) conformation(s), i.e., the conformation of lower energy in mode-
ling computations.
1.1. Modeling of peptides and of biological mechanisms; the rules
1.1.1. Peptide structure and disorder
Peptides, as proteins, are essentially made of L-amino acids. In the
last 15 years, signiﬁcant progresses were made in acknowledging the
existence and understanding the consequences of protein disorder as
reviewed in Ref. [3]. Disorder is an intrinsic property of some proteins
leading to their structural polymorphism. It is due to an insufﬁcient
intramolecular stabilization of their 3D folds or of fragments of these
folds. It results either in movements of backbone ϕ−ψ angles, and thus
affects secondary and tertiary structures, or in movements of few
residues with relative rotations of folded fragments that have more
consequences on tertiary than on secondary structures. Disorder was
initially described for proteins but is undoubtedly a major property of
peptides [2–5]. We recently demonstrated that, irrespective of their
types of 3D folds but depending on a minimal size of about 200–250
residues, stably-foldedglobular proteins have a standard intramolecular
energy value [6]. Peptides never reach the standard value simply
because they are too short to build theminimal network architecture of
a protein domain. Hence, in silicomodeling of 3D structure of peptides
could become an efﬁcient partner of experimental approaches if
calculated models were no longer restricted to the model of lower
energybut opened toproperties of thepopulation of low-energymodels
[2,7].
1.1.2. Peptide disorder and CPP functions
Polymorphism gives functional advantages and disadvantages to
peptides. Peptides exist as populations of conformers of low intrinsic
stability: different partners and media either charged, hydrophobic,
hydrophilic, or interfacial will modify the population equilibrium.
That will help peptides to adapt to external conditions [4,5]. Due to
their larger accessible surfaces and energy of interactions, peptides
bind to partners with a better selectivity than most chemical drugs.
However, polymorphism will decrease their afﬁnity since the energy
spent for the reorganization of 3D conformations diminishes their
binding afﬁnity [8]. This could be interesting for CPPs. They need a
good selectivity for the cargo but not a too high afﬁnity since they will
have to release that cargo at the target. Polymorphism could also
decrease the free CPP bioavailability since a disorder of the backbone
facilitates protease access.
1.1.3. PepLook, an in silico procedure to calculate peptide 3D
conformations
In 2006,we developed PepLook [2], an in silicoprocedure to calculate
populations of 3D structures of peptides from sequences.We calibrated
the algorithm on NMR models and found a good adequation between
experimental and in silico data ever since. PepLook runs a boltzmanian
stochastic procedure [9] that implicates iterative calculations of 3D
models with the modiﬁcations of some input parameters at each
iteration. In PepLook, the parameters that are modiﬁed are the set of
backbone ϕ−ψ angles. The calculation starts with a set of 64 couples of
angles that we derived from a list of pentapeptides published to give a
good coverage of most PDB models of proteins [10]. When calculations
are starting, all couples of angles have equal probability of sorting. Along
calculations, relative probabilities of each couple vary according to their
chance to give good or bad structural solutions. But if a pure stochastic
procedure would discard the ϕ−ψ values of bad solutions, our
boltzmanian procedure only decreases their probability, giving a chance
to re-use them later in the calculation, i.e., when part(s) of the peptide
structure has (have) been stabilized. At the endof the calculation, the 99
to999models of lower energy are selected.Model energy values includesemi-empirical terms for intra- and extramolecular energy. Intramo-
lecular energy terms are Van derWaals that globally accounts for steric
constraints [11], Coulomb that accounts for electrostatic interactions,
and hydrophobicity that accounts for the non-interaction of apolar
atoms with water [2]. Extramolecular terms mimic interactions of the
peptide with the medium; they have been developed since the last
30 years by the group of R. Brasseur [12–15]. They mimic hydrophilic,
hydrophobic, and interfacial environments.
1.1.4. Modeling of biological mechanisms
Modeling of biological mechanisms starts from 3D models of
molecules and studies their interactions. Analyses can be achieved via
several types of approaches corresponding to different scopes and
aims that we shall here brieﬂy comment with respect to the problem
of CPP–cargo mechanisms. If a biological mechanism is experimen-
tally well documented, then we know which models of molecules are
partners and the medium composition. Dynamics steps of the mech-
anism are explored: heavy computation systems analyze movements
of the molecule(s) of interest and of the environment. All atoms are
described for time scale of nanoseconds [16,17]. Such procedures can
use coarse-grained (i.e., clustered atoms) descriptions of molecules to
shorten calculations, and they give excellent results. For instance,
heavy computation systems were used to analyze the pushed/pulled
transfer of CPP across membranes. They demonstrated that polymor-
phism of TAT is useful for its membrane permeability [17]. However, if
a biological mechanism is not documented, modeling will be used as a
screening approach and will implicate many tests. This is not
compatible with heavy computation systems. When the mechanism
of formation and transfer of a non-covalent CPP–cargo complex is
studied, the experimental knowledge is far from molecular details.
Realistic approaches should cover at least the complex formation from
CPPs and a cargo, the formation of nanoparticles from complexes, the
interaction of complexes and nanoparticles with proteoglycan, the
transfer across cell membranes, the destabilization of complexes, and
ﬁnally, the targeting of cargo to its intracellular target. Modeling has
means to address such problems: their goal is to test several sets of
conditions and partners in order to screen different possibilities to
decipher which could be energetically sound. The prerequisite of such
approaches is to shorten computations, for instance, by using rigid
molecules and slab models of membranes. Their successes depend
upon the relevance of those latter choices. Such approaches led in the
past to important discoveries as “tilted peptides”, i.e., short sequences
of the fusion proteins of viruses with special hydrophobicity patterns
that were shown to disturb parallel arrangement of lipid acyl chains
and suggested to trigger fusion processes [18–20]. They were also
used to propose an explanation to the selectivity of CRAC motifs for
cholesterol [21]. Models were small molecules and complexes, and
the extrapolation to large complexes as the CPP–cargo is a challenge
that the increase in computer capacities makes conceivable.
1.2. Modeling of CPP Cargoes mechanisms; the partners
1.2.1. The cargoes
Several types of molecules are transported, from polypeptides to
nucleic acids [1] (Table 1). Polypeptides can be proteins and peptides;
nucleic acids can be DNA, RNA, PNA, and siRNA. Other cargoes can be
liposomes and nanoparticles. Cargoes differ by their size and com-
position, by their charge and polarity, and by their stability (Fig. 1).
Differences of size and hydrophobicity will be important for
permeability andmodeling approaches cannot assume that all cargoes
will be transported the same way. Classes of cargoes must and will be
made.
In this article, we shall restrict our analysis to the transfer of a non-
covalent complexandwill takeasexamplea siRNAmolecule transported
by CADY. The SiRNA 3Dmodel in Fig. 1 is more or less a cylinder of 77 Å
long, and 27 Åminimal width. It is highly polar due to the abundance of
Table 1
Representative partners of CPP–cargo transfer mechanisms: CPP sequences, origin of sequences, cargo types, protocols of cargo–CPP docking, and major references. Modiﬁed from
F. Heitz et al. [1].
Peptides Origin Sequences Cargoes CPP–Cargo Link References
TAT HIV-Tat protein PGRKKRRQRRPPQ Protein; peptide Covalent [22]
Liposome; nanoparticle Covalent [23]
Penetratin Homeodomain RQIKIWFQNRRMKWKK siRNA (TAT-RBD) Complex [24]
Peptide; siRNA; liposome Covalent [25]
Transportan Galanin-mastoparan GWTLNSAGYLLGKINLKALAALAKKlL Protein/PNA/siRNA Covalent [26]
TP10 Transportan mutant AGYLLGKINLKALAALAKKIL Protein/PNA Covalent [27]
VP-22 HSV-l structural protein DAATATRGRSAASRPTER Protein Covalent [28]
PRAPARSASRPRRPVD
MPG HIV Gp41-SV 40 NLS GALFLGFLGAAGSTMGAWSQPKKKRKV siRNA/ODN/plasmid Complex [29]
MPG-8 MPG mutant AFLGWLGAWGTMGWSPKKKRK siRNA Complex [30]
Pep-l, -2 and -3 W-rich motif-SV 40 NLS KETWWETWWTEWSQPKKKRKV Protein/Peptide Complex [31]
MAP Chimeric KALAKALAKALA Small molecule/plasmid Covalent [32]
SAP Proline-rich motif VRLPPPVRLPPPVRLPPP Protein/Peptide Covalent [33]
PPTG1 Chimeric GLFRALLRLLRSLWRLLLKA Plasmid Complex [34]
CADY Chimeric GLWRALWRLLRSLWRLLWRA siRNA Complex [30]
Oligoarginine Chimeric R8 or R9 Protein/Peptide/siRNA/ODN Covalent and complex [35,36]
hCT (9-32) Human calcitonin LGTYTQDFNKTFPQTAIGVGAP Protein/Plasmid DNA Covalent [37]
SynB Protegrin RGGRLSYSRRRFSTSTGR Doxorubicin Covalent [38]
Pvec Murine V E-Cadherin LLIILRRRIRKQAHAHSK Protein/Peptide Complex [39]
S413-PV Chimeric ALWKTLLKKVLKAIPKKKRKVC Protein/Peptide Covalent [40]
2219A. Thomas et al. / Biochimica et Biophysica Acta 1798 (2010) 2217–2222accessible phosphate groups with a ratio of hydrophobic/hydrophilic
accessible surface of 0.39. The same ratio is 1 for most soluble proteins
[41], is 0.8 for the Green Fluorescent Protein that is carried into cells by
Pep1, is 0.7 for a PNA model (Fig. 1), and is more than 1 for classical
membrane proteins [41]. Because of its hydrophilicity, siRNA is unlikely
to cross a membrane, and one of the role of CADY will be to decrease its
apparent hydrophilicity.
The 3D structure of siRNA is more rigid and larger than that of
CADY. Hence CADY will be the surrounding partner, and several CADY
will be required per siRNA. The same is true for other cargoes as PMOs,
RNA, DNA, and proteins, but the number of CPPs that will surround a
peptide should be less.Fig. 1. Structural models of cargoes and CPP. Three cargoes are shown, a protein (GFP; pdb2
atom colors, and middle in their MHP outlook [14]. MHP are isopotential hydrophobicity sur
listed in columns: ASA ratio, L, and l. ASA ratio is the ratio of the hydrophobic to hydrophilic
the width of the 3D model in Angstroms. Figures were prepared using Pymol and WingMG1.2.2. The CPP
Their discovery and history were reviewed by F. Heitz et al. [1].
Carriers constitute a more homogeneous family than cargoes, at least
considering their size; CPPs are peptides of 20–30 residues and most
contain several positively charged amino acids. Unlike carboxylic acids
that can interact one with the other via H-bonds, positively charged
residues (arginine and lysine) are repulsive partners. CADY has 5
arginine, hence a risk of polymorphism due to repulsive intramolec-
ular interactions and of avidity for anionic external partners [42–44].
For CADY, interactions with anionic partners could occur with three
partners of themechanism, themembrane lipid polar heads, the siRNA
cargo, and proteoglycans.WSN) a siRNA (pdb 2Z10), a PNA (pdb 1XJ9) left in their CPK outlook with the current
faces, green is hydrophilic, brown is hydrophobic− 0.1 kcal. On the left, three values are
surface area of water-accessible atoms of the 3D model. L is the maximal length, and l is
M.
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the water/membrane interface and are either globally negative or
neutral. A charged lipid as DOPG has the negative charges of phos-
phate and carbonyl groups. Zwitterionic lipids have phosphate
charges and positive charges as choline in DOPC. Hence, arginine of
CADY will interact with negative charges of lipids [42,43]. It should
give to CPPs an opportunity to selectively approach and bind to a
membrane surface. Another factor should facilitate CADY insertion in
membrane, its apparent hydrophobicity. Despite their numerous
positive charges, hydrophobic/hydrophilic accessible surface ratio of
CPPs (CADY, transportan, Pep1–3) are higher than 1, hence they are
hydrophobic even in water in agreement with the experimental facts
that they are more soluble in membrane (interface) than in water and
that they tend to aggregate in phosphate buffer (Fig. 1).
We used PepLook to calculate CADY and other CPP 3D struc-
tures [2,7,45,46]. Unlike the non-CPPmagainin that PepLook describes
as structurally monomorphic, all CPPs that were analyzed up to now
are polymorphic (Fig. 2): some, as the hCT 9–32, a fragment of the
human calcitonin, are highly polymorphic with changes of backbone
architecture; others as transportan have ordered N- or C-ends.
PepLook properties of CADY and of its derivative R19K support that
they are polymorph except in their centers. The central fragment is
helical. Experimental assays demonstrated that CADY is more helical
in DOPG than in water [45]. Energy proﬁle of PepLook models
supports the analysis that binding of the arginine of CADY to a counter
anion decreases intramolecular Arg–Arg repulsions, decreasing the
electrostatic energy term, a major factor of the polymorphism. An all-
helix conformation of CADY would be optimal for the segregation of
hydrophobic and hydrophilic residues and thus favorable for the
hydrophobicity energy term. Hence, decreasing the Arg–Arg repulsion
can explain why, in experimental assays, CADY ismore helical in lipids
than in water. However, the helical ratio of CADY in PepLook models
plateaus to 60% with three distinct helical fragments instead of a
continuous helix. The helix would, however, orientate all arginine on
one side for their interactions with phosphates and all tryptophan on
the other inducing further insertion in membranes [36]. Hence,
PepLook data support that steric restrictions (Van der Waals energy
term) of bulky residues could be responsible to impair the formation
of the long helix. Tryptophan are important in the function of CADY,
and the reasons of their importance are unclear. Part of it could beFig. 2. Ribbon image of the 20 PepLook lower energy models of magainin (A), CADY
(B), Transportan (C), and Penetratin (D) in water. The ﬁgures were prepared using
Qmol.a structural restriction. The hypothesis is sustained by the data
presented here but remains to be validated.
1.3. Modeling approaches of CPP–cargo complexes
Two experimental protocols are currently used to prepare CPP–
cargo mixtures (Table 1). Either one carrier is covalently linked to one
molecule of cargo or several free CPPs are pre-incubated with a cargo
to form a non-covalent stable complex with a CPP/cargo ratio higher
than 1. Carrier peptides used in the two approaches were initially
different, but more recent experiences use the same CPP for both
types of assays. Transportan and some of its mutants (Tp10 and
derivatives) were covalently bound for delivering proteins, PNA, and
siRNA, and they are now tested in non-covalent complexes [47]. TAT
was covalently bound for delivering proteins, peptides, liposomes,
and nanoparticles and has been recently tested in non-covalent
complexes for delivering siRNAs [48]. Among the non-covalent CPPs,
MPG is forming deliverable complexes with siRNA and plasmids [49],
CADY is transporting siRNA [30] and Pep-1 to -3 are transporting
peptides and proteins [50].
It is clear that the size of cargo–CPP complexes will be proportional
to the size of their components. CADY in water is an elongated form
about 34×23 Å (3.4×2.3 nm), the siRNA model is more or less a
cylinder of 77×27 Å (7.7×2.7 nm) (Fig. 1). On experimental bases,
15–20 molecules of CADY are required to stabilize a CADY–siRNA
complex [46]. We calculated the complex in silico and found a 105 ×
76 nm (10.5×7.6 nm) particle [manuscript in preparation]. It is
interesting to point out that the complex is much smaller than the
large aggregates (200- to 300-nm nanoparticles) that were shown by
different experimental approaches and are used as the stable CPP–
cargo entities for in vivo delivery [51,52]. In fact, a 200- to 300-nm
aggregate might contain several thousands of the [1 mole of siRNA+
15–20 mol of CADY] complex particle.
Last but not the least, when mechanisms of permeability are
questioned, other parameters must be considered. The lipid bilayer of
a membrane has an averaged thickness of 4 to 5 nm and the surface
glycocalyx thickness varies from 10 to 100 nm with cell types. Hence,
a complex particle of CADY–siRNA (10.5×7.6 nm) is about twice a
membrane bilayer thickness and, a 200- to 300-nm nanoparticle is
40–60 times larger than this membrane. Note that when glycocalyx is
considered, the 200- to 300-nm aggregates could be in the range of
some coat thickness.
1.4. The CPP–cargo complex uptake
Several mechanisms of uptake have been evoked, from direct
transfer of CPP–cargo complexes through the membrane [46] up to
endocytotic processes of diverse forms of CPP–cargo complexes [53].
From the above data, we suggest that the 200- to 300-nmnanoparticles
are much too big to simply cross a membrane without damaging it.
Nevertheless, these nanoparticles were seen at the membrane vicinity.
They could be bound to andpartiallywrapped in glycocalyx. Attached to
glycocalyx, nanoparticles could serve as reservoir of the smaller
complex around 1 siRNA, the size of which is more compatible with a
direct uptake mechanism.
1.5. Free CPP permeability
Of course, based on these considerations of molecule and complex
sizes, we also suggest that their uptake by cells must bemechanistically
different from uptakes of free CPP molecules. Non-covalent CPP–cargo
complexes are prepared in buffered or non-buffered water solutions
prior to anyexposition toa biologicalmaterial. TheCPPand thecargo are
thus initial partners, the cell membrane being a second-step partner.
The protocol is differentwhen permeability of isolated CPP is tested: the
CPP is directly in contact with a membrane and will spontaneously
2221A. Thomas et al. / Biochimica et Biophysica Acta 1798 (2010) 2217–2222interfere with proteoglycans and with lipid polar heads. In a previous
article [7], we proposed that the polymorphism of CPP is required to
explain their innate capacity of uptake. Polymorphism, together with
selective interactions with polar heads of lipids, is indeed implicated in
themechanism of peptide transfer in theoretical models [17]. However,
shouldwe link free CPP permeability to themechanism of non-covalent
CPP–cargo complex permeability? This is not sure and might be a
restrictive choice. Improving the transfer of large cargo–CPP complexes
might require properties thatwill not be optimal for the permeability of
free CPP. Completemodeling approaches ofmechanisms of transferwill
step by step examine and discuss these points further.2. Conclusions
This article presents very basic points of CPP–cargo mechanism of
permeability in relation with experimental data. A realistic screening
modeling approach could be helpful for deciphering this multi-steps
mechanism. We do not discuss covalent 1 to 1 cargo–CPP complexes:
they could bemore dependent on free CPP properties than the transfer
of non-covalent CPP–cargo complexes. The siRNA–CADY complexes
implicate 15 to 20 CADY per cargo [46]. These unitary complexes were
also shown to form large super aggregates or nanoparticles. The
nanoparticles are expected to be more stable for therapeutic applica-
tions. Based on PepLook properties of CADY, we propose some clues to
understand the peptide structure properties. Based on size considera-
tions, we suggest that siRNA–CADY nanoparticle could adsorb on the
glycocalyx and act as reservoir of the membrane-permeable smaller
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